Optimising drug dosing in patients receiving extracorporeal membrane oxygenation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Optimal pharmacological management during extracorporeal membrane oxygenation (ECMO) involves more than administering drugs to reverse underlying disease. ECMO is a complex therapy that should be administered in a goal-directed manner to achieve therapeutic endpoints that allow reversal of disease and ECMO wean, minimisation of complications (treatment of complications when they do occur), early interruption of sedation and rehabilitation, maximising patient comfort and minimising risks of delirium. ECMO can alter both the pharmacokinetics (PK) and pharmacodynamics (PD) of administered drugs and our understanding of these alterations is still evolving. Based on available data it appears that modern ECMO circuitry probably has a less significant impact on PK when compared with critical illness itself. However, these findings need further confirmation in clinical population PK studies and such studies are underway. The altered PD associated with ECMO is less understood and more research is indicated. Until robust dosing guidelines become available, clinicians will have to rely on the principles of drug dosing in critically ill and known PK alterations induced by ECMO itself. This article summarises the PK alterations and makes preliminary recommendations on possible dosing approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 1×
“Optimal antibiotic therapy has been shown to correlate with improved patient outcomes (37-39) and this strategy often underpins the primary treatment goal in this patient population.”
BackgroundDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“The beta-lactam’s optimal bactericidal killing is achieved when the free (unbound) drug concentration remains four-to-five times above the minimum inhibitory concentration (MIC) of a pathogen for extended periods during a dosing interval (fT>MIC) (54,55).”
BackgroundRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046 · cited 2×
“Extreme PK changes in critically ill patients have been well described (14), and the introduction of ECMO appears to have added an additional level of complexity and importantly, another variable inadequately characterised in adult critical care management (15).”
BackgroundSelf-citationOptimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria
Kashuba, A. D. M., Nafziger, A. N., Drusano, G. L., & Bertino, J. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.623 · Cited by 380 · cited 1×
“Aminoglycoside exhibits concentrationdependent bacterial killing and optimal therapeutic outcomes have been associated with achieving a ratio of peak drug concentration (Cmax) to MIC (Cmax/MIC) ratio of 10–12 (69) and an AUC0–24/MIC ratio of 80–160 (70).”
BackgroundDeterminants of drug absorption in different ECMO circuits
Wildschut, E. D., Ahsman, M. J., Allegaert, K., Mathot, R. A. A., & Tibboel, D. (2010) · Intensive Care Medicine · doi:10.1007/s00134-010-2041-z · Cited by 254 · cited 3×
“This, among other findings (18,24,27,32,33), may likely stem from the result of morphine being less lipophilic (68), and consequently, making it a superior clinical option as opposed to fentanyl in the management of ECMO patients.”
BackgroundDagan, O., Klein, J., Gruenwald, C., Bohn, D., Barker, G., & Koren, G. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199308000-00001 · Cited by 107
Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation
COHEN, P., COLLART, L., PROBER, C. G., FISCHER, A. F., & BLASCHKE, T. F. (1990) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199008000-00007 · Cited by 80
Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation
Bhatt‐Mehta, V., Johnson, C. E., & Schumacher, R. E. (1992) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1992.tb02667.x · Cited by 70
Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation
Southgate, W. M., DiPiro, J. T., & Robertson, A. F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.6.817 · Cited by 50
Cited by
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Self-citation
Metadata
- Authors
- Cheng, V., Abdul-Aziz, M.-H., Roberts, J. A., & Shekar, K.
- Venue
- Journal of Thoracic Disease
- Publisher
- AME Publishing Company
- Published
- 2018-03
- Volume
- 10
- Issue
- S5
- Pages
- S629-S641
- ISSN
- 2072-1439 (ISSN-L)
- 2077-6624
- OpenAlex
- W2765105161
- Cited by
- 177
- References
- 10
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.